Physician profile
Lisa Goecke
NPI 1427772821
$6,510.64
in general payments reported to CMS, 2019-2025
17 companies · $2,427 in 2025
The $2,427 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $66.78 · 2023: $1,910 · 2024: $2,107 · 2025: $2,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,440 · Education: $3.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,440.07 |
| Education | $3.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $886.45 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $844.74 | 2023-2025 | |
| Axsome Therapeutics, INC. | $820.85 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $661.66 | 2024-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $635.65 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $517.47 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $478.87 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $441.46 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $260.50 | 2024-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $258.58 | 2023-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $190.67 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $189.77 | 2023-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $189.66 | 2023 | Quviviq |
| Tempus Ai, INC | $74.05 | 2024 | |
| Luye Pharma (USA) LTD. | $21.96 | 2025 | Erzofri Extended-Release |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $20.24 | 2024 | Azstarys |
| Tris Pharma INC | $18.06 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Goecke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.